Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q01433
UPID:
AMPD2_HUMAN
Alternative names:
AMP deaminase isoform L
Alternative UPACC:
Q01433; A0A5F9UK94; B4DK50; B4DZI5; E9PNG0; Q14856; Q14857; Q16686; Q16687; Q16688; Q16729; Q5T693; Q5T695; Q96IA1; Q9UDX8; Q9UDX9; Q9UMU4
Background:
AMP deaminase 2, also known as AMP deaminase isoform L, plays a pivotal role in energy metabolism by catalyzing the deamination of AMP to IMP. This process is crucial in the purine nucleotide cycle, highlighting the enzyme's importance in cellular energy homeostasis.
Therapeutic significance:
The enzyme's association with diseases such as Pontocerebellar hypoplasia 9 and Spastic paraplegia 63 underscores its potential as a therapeutic target. Understanding the role of AMP deaminase 2 could open doors to potential therapeutic strategies, offering hope for patients suffering from these debilitating conditions.